Clinical trials
Nephropathy clinical trials
Below are recruiting nephropathy clinical trials, each written for real people, not researchers. We’re tracking 151 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07054684RecruitingPhase 1
Study of BHV-1400 for IgA Nephropathy
This trial tests a new medicine, BHV-1400, for people with IgA Nephropathy, a kidney disease. The goal is to see if it can help slow down kidney damage.
Farmington, ConnecticutAges 18–65 - NCT07038213Enrolling by invitation
Study of kidney protection in type 2 diabetes
This study looks at how genes may affect kidney disease in people with type 2 diabetes. It tests treatments to protect the kidneys. If you are of Kazakh ethnicity and have type 2 diabetes, you may be able to join.
AstanaAges 18–65 - NCT07030894RecruitingPhase 4
Study of Nefecon and Ambrisentan for IgA Nephropathy
This trial tests two medications, Nefecon and Ambrisentan, to see if they can help people with IgA nephropathy, a kidney disease. It may be an option if you have been diagnosed with IgA nephropathy in the last 4 years and have protein in your urine.
Changchun, JilinAges 18–70 - NCT07014826RecruitingPhase 3
Trial of HRS-5965 for IgA kidney disease
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07010250Recruiting
Kidney Energy Use and Scarring in ANCA Vasculitis
This study looks at how kidney cells use energy and how that leads to scarring in people with ANCA vasculitis. It compares findings with people who have other kidney diseases to better understand and possibly treat kidney damage.
ParisAges 18–90 - NCT06982729RecruitingPhase 1
Testing YK012 for primary membranous nephropathy
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
Beijing, Beijing MunicipalityAges 18–80 - NCT06962800RecruitingPhase 3
Study of felzartamab for adults with primary membranous nephropathy
This study tests whether felzartamab, given as an infusion, can help treat primary membranous nephropathy (a kidney disease causing protein in the urine and swelling). It may reduce protein loss and improve kidney function compared to standard care alone.
Huntsville, AlabamaAges 18–80 - NCT06952426Recruiting
IgA Nephropathy app study for patients and caregivers
This study uses a mobile app to track how IgA nephropathy (IgAN) affects daily life and what treatments people use. It’s open to patients and their caregivers to help researchers learn more about the disease.
Boston, MassachusettsAges 18 years+ - NCT06935357RecruitingPhase 3
Felzartamab infusions for IgA nephropathy
This study tests a new drug called Felzartamab (given as an infusion) for people with IgA nephropathy (IgAN), a kidney disease. The goal is to see if it can reduce protein leaking into urine and protect kidney function.
Little Rock, ArkansasAges 18 years+ - NCT06926244Recruiting
Studying resistance to IgA nephropathy treatments in real life
This study observes how people with IgA nephropathy respond to standard and newer treatments in everyday medical practice, to understand why some cases are resistant to therapy.
ParisAges 18 years+ - NCT06676384RecruitingPhase 4
Testing additional drugs for IgA nephropathy in South Asian patients
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
Nadiād, GujaratAges 18–65 - NCT06781944RecruitingPhase 3
Obinutuzumab vs standard treatment for membranous nephropathy
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06676579RecruitingPhase 2
Avacopan for active IgA kidney disease with crescents
This trial tests if avacopan, a targeted anti-inflammatory drug, can safely treat a severe form of IgA nephropathy (IgAN) where small crescents form in the kidney filters. It may help reduce protein leakage and preserve kidney function.
Jacksonville, FloridaAges 18 years+ - NCT06676007Recruiting
Early use of a targeted budesonide for IgA nephropathy
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
Chengdu, SichuanAges 18–75 - NCT06573411RecruitingPhase 4
Finerenone for primary membranous nephropathy
This trial tests if finerenone, a medicine that may protect the kidneys, can help people with primary membranous nephropathy (a kidney disease that causes protein in urine). It is for adults who are already taking a standard blood pressure medicine but still have protein in their urine.
Guangzhou, GuangdongAges 18 years+ - NCT06470191RecruitingPhase 2/Phase 3
B007 for primary membranous nephropathy
This trial tests a new drug called B007 for people with primary membranous nephropathy, a kidney condition. It aims to see if B007 can help reduce protein in the urine and protect kidney function.
BeijingAges 18–80 - NCT06469190RecruitingEarly Phase 1
CAR NK cells for treatment-resistant kidney disease
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
ShanghaiAges 18–70 - NCT06350630RecruitingPhase 2
Hydroxychloroquine for IgA nephropathy
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
Clermont-FerrandAges 18 years+ - NCT06341205RecruitingPhase 3
Personalized rituximab for membranous nephropathy using AI
This trial tests if an artificial intelligence tool can help doctors decide the best dose and timing of rituximab for people with a kidney condition called membranous nephropathy. It aims to improve treatment results and reduce side effects.
BesançonAges 18 years+ - NCT06242327Recruiting
Study of outcomes in primary membranous nephropathy
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
Bergamo, BGAges 18 years+ - NCT05696613RecruitingPhase 3
Study of a hormone gel for high-risk membranous nephropathy
This study tests a new gel that contains a natural hormone to quiet the immune attack on kidneys. It is for people whose membranous nephropathy is at high risk of getting worse.
Los Angeles, CaliforniaAges 18 years+ - NCT05668403RecruitingPhase 1
Subcutaneous anti-CD20 antibody for primary membranous nephropathy
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
Zhengzhou, He'nanAges 18–75 - NCT05505500Recruiting
Parent and patient interviews for childhood kidney swelling
This study uses interviews to understand how swelling from nephrotic syndrome affects daily life for children and their caregivers. It may help researchers design better care by capturing the patient and parent perspective.
Ann Arbor, MichiganAges 2 years+ - NCT05248659Enrolling by invitationPhase 2/Phase 3
Sibeprenlimab for IgA kidney disease after prior study
This trial studies sibeprenlimab to see if it can improve IgA nephropathy, a kidney inflammation condition. You may be able to join if you finished a previous related Otsuka study without major safety problems and your doctor thinks you could benefit.
Birmingham, AlabamaAges 18 years+
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nephropathy?
- Yes. Clin2 currently lists 151 recruiting nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.